Kestra Private Wealth Services LLC Acquires 13,331 Shares of Novo Nordisk A/S (NYSE:NVO)

Kestra Private Wealth Services LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 37.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,640 shares of the company’s stock after acquiring an additional 13,331 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Novo Nordisk A/S were worth $4,184,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in NVO. Exchange Traded Concepts LLC boosted its stake in shares of Novo Nordisk A/S by 40.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 63,962 shares of the company’s stock worth $7,616,000 after acquiring an additional 18,370 shares during the period. Procyon Advisors LLC boosted its stake in Novo Nordisk A/S by 6.7% in the 3rd quarter. Procyon Advisors LLC now owns 63,649 shares of the company’s stock valued at $7,579,000 after purchasing an additional 4,010 shares during the period. ORG Wealth Partners LLC bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at $313,000. Sapient Capital LLC boosted its stake in Novo Nordisk A/S by 0.7% in the 3rd quarter. Sapient Capital LLC now owns 640,279 shares of the company’s stock valued at $76,238,000 after purchasing an additional 4,429 shares during the period. Finally, Adamsbrown Wealth Consultants LLC boosted its stake in Novo Nordisk A/S by 13.8% in the 3rd quarter. Adamsbrown Wealth Consultants LLC now owns 1,916 shares of the company’s stock valued at $228,000 after purchasing an additional 233 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 2.9 %

Shares of Novo Nordisk A/S stock opened at $83.90 on Tuesday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75. The stock’s 50-day moving average is $91.46 and its 200 day moving average is $111.21. The firm has a market cap of $376.48 billion, a price-to-earnings ratio of 25.50, a PEG ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 21.88%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.